ADVERTISEMENT
Dr. Reddy's Q1 Results Review - Limited Upside: Dolat Capital
The brokerage upgrades its FY25E/FY26 EPS estimates by 6.9%/4.5% assuming higher than expected gRevlimid and India sales.
29 Jul 2024, 11:38 AM IST 
Picture for representation purposes only. (Source: Dr. Reddy's Laboratories/X)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
I’m already a Subscriber Sign In
To continue reading this storySubscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
